- Home
- THCH vs ICCC Comparison
THCH vs ICCC Comparison
Compare THCH & ICCC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THCH | ICCC |
|---|---|---|
| Founded | 2018 | 1982 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.9M | 55.5M |
| IPO Year | 2021 | 1995 |
Fundamental Metrics
Financial Performance| Metric | THCH | ICCC |
|---|---|---|
| Price | $2.01 | $6.39 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.9K | ★ 11.6K |
| Earning Date | 04-14-2026 | 03-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 65.33 |
| EPS | N/A | ★ 0.20 |
| Revenue | N/A | ★ $26,493,169.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $30.40 |
| Revenue Growth | N/A | ★ 51.64 |
| 52 Week Low | $1.69 | $4.52 |
| 52 Week High | $3.25 | $7.60 |
Technical Indicators
Market Signals| Indicator | THCH | ICCC |
|---|---|---|
| Relative Strength Index (RSI) | 47.41 | 50.82 |
| Support Level | $1.69 | $6.06 |
| Resistance Level | $2.71 | $6.84 |
| Average True Range (ATR) | 0.14 | 0.20 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 19.44 | 55.72 |
Price Performance
Historical ComparisonAbout THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. The Company operated under single reportable segment, Tim Hortons. The company's revenue is derived from its operations in the PRC.
About ICCC ImmuCell Corporation
ImmuCell Corp is engaged in the healthcare sector. The company operates in the development, acquisition, manufacture, and sale of products that improve the health and productivity of cows for the dairy and beef industries. The company operates in two business segment. The Scours segment is dedicated to manufacturing and selling First Defense, a product used to prevent scours in newborn calves, which is regulated by the United States Department of Agriculture (USDA). The Mastitis segment is focused on developing and commercializing Re-Tain, a product to treat subclinical mastitis in lactating dairy cows, which is regulated by the United States Food and Drug Administration (FDA). The company generates the majority of its revenue from the Scours segment.